EEF1A2
Basic information
Region (hg38): 20:63488013-63499239
Previous symbols: [ "STNL", "STN" ]
Links
Phenotypes
GenCC
Source:
- developmental and epileptic encephalopathy, 33 (Moderate), mode of inheritance: AD
- autosomal dominant non-syndromic intellectual disability (Supportive), mode of inheritance: AD
- undetermined early-onset epileptic encephalopathy (Supportive), mode of inheritance: AD
- developmental and epileptic encephalopathy, 33 (Strong), mode of inheritance: AD
- complex neurodevelopmental disorder (Definitive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Developmental and epileptic encephalopathy 33; Intellectual developmental disorder, autosomal dominant 38 | AD | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Craniofacial; Neurologic | 23033978; 23647072; 24697219 |
ClinVar
This is a list of variants' phenotypes submitted to
- Developmental and epileptic encephalopathy, 33 (6 variants)
- Intellectual disability, autosomal dominant 38 (2 variants)
- EEF1A2-related developmental and degenerative epileptic-dyskinetic encephalopathy (2 variants)
- not provided (2 variants)
- Inborn genetic diseases (2 variants)
- Intellectual disability (1 variants)
- EEF1A2-related disorder (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the EEF1A2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 180 | 11 | 193 | |||
missense | 22 | 123 | 10 | 163 | ||
nonsense | 3 | |||||
start loss | 0 | |||||
frameshift | 2 | |||||
inframe indel | 3 | |||||
splice donor/acceptor (+/-2bp) | 4 | |||||
splice region | 13 | 32 | 4 | 49 | ||
non coding | 72 | 36 | 108 | |||
Total | 7 | 23 | 136 | 262 | 48 |
Variants in EEF1A2
This is a list of pathogenic ClinVar variants found in the EEF1A2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
20-63488052-G-A | Likely benign (Jan 01, 2024) | |||
20-63488083-G-C | Likely benign (Jul 01, 2024) | |||
20-63488288-C-T | Likely benign (Mar 30, 2021) | |||
20-63488301-C-T | Likely benign (Sep 23, 2020) | |||
20-63488306-CCGCCTTCTG-C | not specified • Developmental and epileptic encephalopathy, 33 | Conflicting classifications of pathogenicity (Dec 27, 2023) | ||
20-63488307-C-T | Developmental and epileptic encephalopathy, 33 • Inborn genetic diseases | Likely benign (Oct 25, 2022) | ||
20-63488308-G-A | Developmental and epileptic encephalopathy, 33 | Uncertain significance (Jan 19, 2024) | ||
20-63488310-C-T | Developmental and epileptic encephalopathy, 33 | Likely benign (May 08, 2023) | ||
20-63488311-T-C | Intellectual disability, autosomal dominant 38 | Uncertain significance (Nov 11, 2021) | ||
20-63488316-C-T | Developmental and epileptic encephalopathy, 33 | Likely benign (Sep 15, 2020) | ||
20-63488321-T-C | Developmental and epileptic encephalopathy, 33 | Uncertain significance (Apr 25, 2022) | ||
20-63488325-C-T | Developmental and epileptic encephalopathy, 33 | Likely benign (Jan 15, 2024) | ||
20-63488334-G-C | Developmental and epileptic encephalopathy, 33 | Likely benign (Nov 05, 2022) | ||
20-63488334-G-T | Developmental and epileptic encephalopathy, 33 | Likely benign (Apr 26, 2022) | ||
20-63488339-C-T | Developmental and epileptic encephalopathy, 33 | Uncertain significance (May 17, 2022) | ||
20-63488345-C-T | Developmental and epileptic encephalopathy, 33 • Intellectual disability, autosomal dominant 38;Developmental and epileptic encephalopathy, 33 | Uncertain significance (May 26, 2022) | ||
20-63488346-G-A | Developmental and epileptic encephalopathy, 33 | Likely benign (Sep 29, 2022) | ||
20-63488346-G-C | Developmental and epileptic encephalopathy, 33 | Likely benign (Sep 19, 2023) | ||
20-63488349-G-A | Likely benign (Apr 20, 2018) | |||
20-63488351-C-T | Developmental and epileptic encephalopathy, 33 | Benign (Jun 04, 2023) | ||
20-63488352-G-A | Developmental and epileptic encephalopathy, 33 | Likely benign (Dec 23, 2021) | ||
20-63488355-G-A | not specified • Developmental and epileptic encephalopathy, 33 • Inborn genetic diseases • EEF1A2-related disorder | Benign (Jan 30, 2024) | ||
20-63488355-G-T | Developmental and epileptic encephalopathy, 33 • Inborn genetic diseases | Uncertain significance (Jun 25, 2022) | ||
20-63488356-CTCT-C | Uncertain significance (Sep 17, 2021) | |||
20-63488358-C-T | Developmental and epileptic encephalopathy, 33 | Likely benign (Dec 12, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
EEF1A2 | protein_coding | protein_coding | ENST00000217182 | 7 | 11140 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.996 | 0.00442 | 124323 | 0 | 1 | 124324 | 0.00000402 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 4.82 | 69 | 306 | 0.225 | 0.0000212 | 3026 |
Missense in Polyphen | 18 | 163.77 | 0.10991 | 1594 | ||
Synonymous | 0.831 | 128 | 141 | 0.911 | 0.0000116 | 933 |
Loss of Function | 3.71 | 0 | 16.0 | 0.00 | 7.83e-7 | 198 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00000897 | 0.00000897 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis.;
- Disease
- DISEASE: Epileptic encephalopathy, early infantile, 33 (EIEE33) [MIM:616409]: A form of epileptic encephalopathy, a heterogeneous group of severe childhood onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. {ECO:0000269|PubMed:23033978, ECO:0000269|PubMed:23647072}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Mental retardation, autosomal dominant 38 (MRD38) [MIM:616393]: A form of mental retardation, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD38 common features are severe intellectual disability, autistic behavior, absent speech, neonatal hypotonia, epilepsy and progressive microcephaly. {ECO:0000269|PubMed:24697219}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Legionellosis - Homo sapiens (human);RNA transport - Homo sapiens (human);Translation Factors;Translation;Metabolism of proteins;Purine metabolism;EGFR1;Eukaryotic Translation Elongation
(Consensus)
Recessive Scores
- pRec
- 0.476
Intolerance Scores
- loftool
- rvis_EVS
- -0.67
- rvis_percentile_EVS
- 15.62
Haploinsufficiency Scores
- pHI
- 0.502
- hipred
- Y
- hipred_score
- 0.851
- ghis
- 0.630
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.881
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Low | Low | Low |
Primary Immunodeficiency | Medium | Low | Medium |
Cancer | Low | Low | Low |
Mouse Genome Informatics
- Gene name
- Eef1a2
- Phenotype
- immune system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); cellular phenotype; muscle phenotype; growth/size/body region phenotype; endocrine/exocrine gland phenotype;
Zebrafish Information Network
- Gene name
- eef1a2
- Affected structure
- head
- Phenotype tag
- abnormal
- Phenotype quality
- decreased size
Gene ontology
- Biological process
- translation;translational elongation;response to inorganic substance;positive regulation of apoptotic process;response to electrical stimulus;positive regulation of lipid kinase activity;regulation of chaperone-mediated autophagy
- Cellular component
- nucleus;cytoplasm;eukaryotic translation elongation factor 1 complex;neuronal cell body;myelin sheath;synapse;cytoplasmic side of lysosomal membrane
- Molecular function
- translation elongation factor activity;GTPase activity;protein binding;GTP binding;translation factor activity, RNA binding;protein kinase binding